Genolimzumab - CBT Pharmaceuticals/Genor BioPharma

Drug Profile

Genolimzumab - CBT Pharmaceuticals/Genor BioPharma

Alternative Names: CBT 501; GB 226; PD-1 antibody - Genor Biopharma; Recombinant humanised anti-PD-1 monoclonal antibody

Latest Information Update: 27 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CBT Pharmaceuticals
  • Developer CBT Pharmaceuticals; Genor Biopharma
  • Class Antineoplastics; Monoclonal antibodies; Small molecules
  • Mechanism of Action Immunostimulants; Programmed cell death-1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Peripheral T-cell lymphoma
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 24 Apr 2018 CBT Pharmaceuticals and CrystalGenomics agree to co-develop and co-promote Genolimzumab and CG 200745 worldwide for Solid tumours (Combination therapy)
  • 23 Apr 2018 CBT Pharmaceuticals and CrystalGenomics plan a phase Ib/II trial for Solid tumours (Combination therapy) by the end of 2018
  • 15 Mar 2018 Phase-II clinical trials in Peripheral T-cell lymphoma (Refractory metastatic disease, Second-line therapy or greater) in China (IV) (NCT03502629)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top